New Mouse Model Offers Breakthrough Insights and Therapeutic Hope for Jansen’s Disease
New Mouse Model Offers Breakthrough Insights and Therapeutic Hope for Jansen’s Disease
We’re thrilled to feature a groundbreaking study that brings clarity to the biological mechanisms underlying Jansen’s metaphyseal chondrodysplasia (JMC), while paving the way toward potential treatments.
In a landmark paper published in PNAS in June 2025, the Jansen’s team of researchers successfully generated a stable mouse model carrying a human PTH1R mutation (T410R) known to cause JMC. Unlike previous models with severe phenotypes, this "humanized" mouse model mirrors critical disease features, such as misshapen bones, disorganized growth plate architecture, and mineral ion imbalances, while allowing normal lifespan and reproduction
Advanced imaging confirmed impaired mineralization and vascularization in growth plates, and key biomarkers such as high serum calcium and suppressed endogenous PTH accurately reflected the human condition. Importantly, early proof-of-concept studies showed that administering a PTH inverse agonist restored mineral balance, confirming the path toward therapeutic intervention.
This model stands as a powerful tool for dissecting the molecular pathways driving JMC and for evaluating the safety and efficacy of new therapies, including inverse agonist ligands.
Read the full publication here: A mouse model of Jansen's metaphyseal chondrodysplasia for investigating disease mechanisms and candidate therapeutics
More publications
- New Insights into Craniofacial Features of Jansen’s Disease
- Vision-Related Challenges in Jansen’s Disease
- New Mouse Model Offers Breakthrough Insights and Therapeutic Hope for Jansen’s Disease
- New Therapeutic Pathway Emerges for Jansen’s Disease
- New Research Sheds Light on Osteocyte Dysfunction in Jansen’s Disease
- New Study Reveals Skeletal Rescue Through Zfp521 Ablation in Jansen’s Mouse Model
- Family Case Study Illuminates Variability in Jansen’s Disease Presentation